CASI Insider Trading Activity and SEC Form 4 Filings
CASI insider trading summary
No open-market insider purchases or sales of CASI Pharmaceuticals, Inc. (CASI) have been reported on SEC Form 4 in the past 12 months.
Latest CASI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 8, 2022 | James Huang | Director | Buy | $143K (33,300 @ $4.28) |
| Sep 7, 2022 | James Huang | Director | Buy | $12K (3,111 @ $4.00) |
| Sep 6, 2022 | James Huang | Director | Buy | $75K (19,162 @ $3.89) |
| Sep 2, 2022 | James Huang | Director | Buy | $1K (400 @ $3.74) |
| Sep 1, 2022 | James Huang | Director | Buy | $44K (11,821 @ $3.72) |
| Aug 31, 2022 | James Huang | Director | Buy | $94K (24,975 @ $3.75) |
| Aug 26, 2022 | James Huang | Director | Buy | $148K (39,527 @ $3.75) |
| Aug 24, 2022 | James Huang | Director | Buy | $19K (5,000 @ $3.75) |
| Aug 23, 2022 | James Huang | Director | Buy | $140K (40,000 @ $3.50) |
| Aug 22, 2022 | James Huang | Director | Buy | $80K (23,105 @ $3.46) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.